Pfizer Inc. 10-Q Summary: Quarter Ended October 1, 2006
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended October 1, 2006, and the nine-month period ended October 1, 2006, compared to the same periods in 2005. Pfizer is a global research-based pharmaceutical company. A significant strategic development during this period was the agreement in June 2006 to sell its Consumer Healthcare business to Johnson & Johnson for approximately $16.6 billion, which is now reported as a discontinued operation.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Oct 1, 2006 | 9 Months Ended Oct 1, 2006 |
|---|---|---|
| Revenues | $12,280 | $35,768 |
| Net Income | $3,362 | $9,888 |
| Diluted EPS | $0.46 | $1.35 |
| Operating Cash Flow (9 months) | $13,118 | |
| Net Financial Assets | $8,067 | |
| Total Debt | $8,069 | |
| Effective Tax Rate (9 months) | 15.6% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 9% in the quarter and 3% for the nine months compared to 2005. This growth occurred despite a 6% revenue reduction in the quarter due to the loss of exclusivity for major products (Zoloft, Zithromax, Neurontin, Diflucan, Accupril/Accuretic) and the suspension of Bextra sales.
- Profitability Surge: Net income increased 112% in the quarter and 85% for the nine months. This was driven by a significant decrease in the effective tax rate (from 34.5% to 15.6% for the nine months) due to tax benefits from the resolution of prior tax positions and a decrease in the estimated U.S. tax provision related to foreign earnings repatriation.
- Discontinued Operations: The Consumer Healthcare business results are now segregated. Income from discontinued operations was $123 million for the quarter and $353 million for the nine months.
- Acquisitions: Pfizer recorded $513 million in merger-related in-process R&D charges in the first nine months of 2006, primarily related to the acquisition of Rinat Neuroscience Corp. and the sanofi-aventis Exubera rights.
Guidance, Outlook, and Risks
- Revenue Outlook: Management expects 2007 and 2008 revenues to be comparable to 2006 (at current exchange rates), revising down from a previous forecast of modest growth due to patent expirations, competition, and currency fluctuations.
- 2006 Targets: Pfizer targets 2006 adjusted diluted EPS of approximately $2.00 and reported diluted EPS of approximately $1.63. Full-year 2006 cash flow from operations is expected to exceed $16 billion.
- Productivity Initiative: The "Adapting to Scale" (AtS) initiative is expected to generate over $2.5 billion in cost savings in 2006. Management plans to further transform the cost structure in 2007 and 2008 to reduce operating expenses below 2006 levels.
- Risks: Key risks include the loss of patent exclusivity for major products (Lipitor, Celebrex, Zoloft), regulatory scrutiny of drug safety, pricing pressures in European markets, and the uncertainty of R&D pipeline approvals. Legal proceedings regarding Norvasc patents are ongoing, though Pfizer has secured favorable rulings in recent trials.
Investor Verification Checklist
- Consumer Healthcare Divestiture: Verify the closing status and final terms of the $16.6 billion sale to Johnson & Johnson, including any regulatory conditions.
- Patent Expirations: Monitor the impact of generic competition on Zoloft (expired June 2006) and Zithromax (expired Nov 2005) on future revenue streams.
- Tax Provision Volatility: Review the sustainability of the 15.6% effective tax rate, which was heavily influenced by one-time tax benefits and adjustments to prior-year repatriation estimates.
- AtS Cost Savings: Track the realization of the projected $2.5 billion in 2006 cost savings from the Adapting to Scale initiative against actual restructuring and implementation costs.
- Share Repurchases: Confirm the execution of the expanded $18 billion share repurchase program authorized in June 2006.